ABS Direct Equity Fund’s Edwards Lifesciences EW Stock Holding History

ABS Direct Equity Fund’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$175K	Buy	+2,100	New	+$173K	0.13%	87

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ABS Direct Equity Fund's EW Position: Q1 2026 in Review

ABS Direct Equity Fund opened a new position in Edwards Lifesciences (EW) in Q1 2026: 2,100 shares worth $175K. The stake represents 0.13% of the portfolio and ranks #87 among its holdings.

1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

ABS Direct Equity Fund held 2,100 shares of Edwards Lifesciences worth $175K as of Q1 2026.
Edwards Lifesciences was a new ABS Direct Equity Fund position in Q1 2026.
Edwards Lifesciences made up 0.13% of ABS Direct Equity Fund's portfolio in Q1 2026, its #87 holding.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.